Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Does hormone therapy for menopause leave a mark on breasts and arteries?

NCT ID NCT07810959

Knowledge-focused Sponsor: Sanliurfa Mehmet Akif Inan Education and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are observing 120 postmenopausal women aged 45 to 60 to see whether menopausal hormone therapy is linked to changes in breast density and the thickness of the carotid artery wall. About 70 women receive hormone therapy as part of their routine care, and 50 do not. Over 12 months, the team tracks breast imaging findings, artery measurements, menopausal symptoms, and heart-related health markers. The study does not assign treatment; it simply follows what happens in each group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
menopausal hormone therapy
What this could lead to
If researchers find a link between hormone therapy and changes in breast density or artery thickness, it could help women and doctors weigh the trade-offs of treating menopausal symptoms.
What could go wrong
This observational study cannot prove cause and effect, only associations. The 120 participants may not represent all postmenopausal women, and 12 months is a short window for detecting meaningful changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Postmenopausal women aged 45-60 years, including women receiving systemic menopausal hormone therapy and a control cohort not receiving systemic menopausal hormone therapy.

Ages

45 to 60 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 45-60 years * Postmenopausal status, defined as at least 12 months of amenorrhea since the final menstrual period * Presentation with menopausal symptoms * Baseline breast ultrasonography available * Mammographic imaging performed within the previous 12 months * Ability to comply with the 12-month follow-up protocol * Provision of written informed consent Exclusion Criteria: * Perimenopausal status * Use of any menopausal hormone therapy within the previous 6 months * History of breast cancer or active breast cancer * Suspicious breast lesion at baseline imaging (BI-RADS category 4 or higher) * Unexplained uterine bleeding * Absolute contraindication to menopausal hormone therapy, including active thromboembolic disease, previous myocardial infarction, or active liver disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopause are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Menopause

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Acıbadem Bursa Hospital

    RECRUITING

    Bursa, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.